Nektar Therapeutics provided earnings guidance for the year 2023. GAAP revenue for the full year 2023 is expected to be between $80 million and $90 million. This revenue includes $65 million to $70 million in noncash royalties and $15 million to $20 million in product sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | -0.28% | 0.00% | +209.73% |
May. 09 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M | MT |
May. 09 | Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+209.73% | 321M | |
+34.35% | 705B | |
+29.39% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+14.11% | 238B | |
-3.03% | 210B | |
+10.02% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar Therapeutics Provides Earnings Guidance for the Year 2023